By creator to www.docwirenews.com
This text was initially printed here
Clin Transplant. 2021 Nov 19:e14541. doi: 10.1111/ctr.14541. On-line forward of print.
Transplant facilities have traditionally been reluctant to proceed with kidney transplantation in people with plasma cell dyscrasias (PCDs) attributable to concern for prime charges of PCD recurrence and PCD-related mortality. As novel therapies for PCDs have improved hematologic outcomes, methods to optimize kidney transplantation in people with PCD-mediated kidney illness are wanted. On this single-center case collection we talk about our protocol for the transplantation of people with ESKD attributed to PCD in addition to the hematologic and allograft outcomes of 12 kidney transplant recipients with ESKD attributed to PCD. Median follow-up time after kidney transplantation was 44 months (IQR 36, 84). All sufferers had a functioning allograft one yr after kidney transplantation. 9/12 sufferers had been alive and had a functioning allograft 5 years after kidney transplantation. 5 sufferers skilled relapse of PCD (of whom three responded nicely to subsequent therapies) and 4 sufferers developed secondary malignancies, together with three sufferers with urologic malignancies. This case collection demonstrates that sufferers with kidney illness attributed to PCD have favorable outcomes with kidney transplantation. Transplant analysis in sufferers with PCDs ought to contain a multidisciplinary workforce of transplant nephrologists and oncologists to pick out acceptable candidates. Suppliers ought to take into account screening for urologic malignancies pre- and post-transplantation. This text is protected by copyright. All rights reserved.
PMID:34797567 | DOI:10.1111/ctr.14541
— to www.docwirenews.com